Using a pan-class I PI3K inhibitor (buparlisib), Niessner et al. demonstrated diminished AKT activity, decreased cell growth and proliferation, and increased apoptosis in numerous metastatic melanoma cell lines with various mutational profiles. This evidence concerns the gene AKT1 and metastatic melanoma.